Skip to main content

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race

Written by Customer Service on . Posted in Public Companies.

Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not be

Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) — PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron.”

As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remaining 95%. Clinical efficacy across leading programs is converging in the 12–16% weight-loss range.

In this increasingly competitive field, long-term differentiation depends not only on clinical performance but also on the strength and defensibility of each program’s patent portfolio.

The report reviews more than 1,200 patent documents across 26 clinical-stage programs, mapping composition-of-matter claims, Markush scope, formulation layers, and method-of-use protection. The findings reveal dramatic disparities in patent depth between programs at similar development stages.

More than $47 billion in GLP-1-related deal value has been committed since 2023, yet most oral programs remain unpartnered. With semaglutide’s patent cliff approaching in 2031 and tirzepatide’s in 2036, long-term exclusivity will determine which assets become franchises and which face early generic pressure.

“When multiple drugs deliver similar weight-loss results, the competitive moat shifts beneath the surface,” said Javier Chamorro, Chief Operating Officer of PatentVest. “The difference between a broad genus claim and a narrow composition patent can determine who owns this market for the next twenty years.”

This analysis maps 50 oral small-molecule GLP-1 programs worldwide, including 30 in clinical development, and evaluates the IP positioning of leading assets from Eli Lilly, Novo Nordisk, Pfizer, Roche, AstraZeneca, Gilead, Structure Therapeutics, and others.

This is the first in a series of deep-dive analyses evaluating the structural and patent defensibility of each major program.

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. Powered by a proprietary global IP database and a rigorous diligence methodology, PatentVest delivers actionable intelligence that reveals the structural advantages hidden beneath technology markets.

Read the full report here: https://insights.patentvest.com/https/www.patentvest.com/patentvest-pulse/the-oral-small-molecule-glp-1-race-beyond-orforglipron.

For more information or inquiries, please contact info@patentvest.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.